Search results for "Sarcomatoid"

showing 3 items of 3 documents

Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas

2022

Undifferentiated sarcomatoid carcinoma (USC) of the pancreas is a rare but especially aggressive variant of pancreatic ductal adenocarcinoma (PDAC), composed of at least 80% of sarcomatoid cells. This study aimed to elucidate its clinicopathological and molecular features. The study cohort included 10 patients with pancreatic USC. Clinicopathological parameters were determined for each patient. The molecular profile was investigated using next-generation sequencing (NGS). Histologically, all tumors were hypercellular neoplasms with spindle-shaped or sarcomatoid cells. All patients showed vascular and perineural invasion. Most patients had a poor prognosis. NGS showed important similarities …

GenomicsPancreatic cancerAdenocarcinomaKRAS; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Sarcomatoid; UndifferentiatedSarcomatoidPathology and Forensic MedicineKRAS Pancreatic cancer Pancreatic ductal adenocarcinoma Sarcomatoid UndifferentiatedPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Pancreatic ductal adenocarcinomaMutationUndifferentiatedKRASHumansMyeloid Cell Leukemia Sequence 1 ProteinPancreasCarcinoma Pancreatic Ductal
researchProduct

Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study

2021

Background: Renal cell carcinoma with sarcomatoid differentiation is a highly aggressive form of kidney cancer. Objective: We aimed to analyze the outcomes of patients treated with cabozantinib for metastatic renal cell carcinoma with sarcomatoid features. Methods: We retrospectively collected data from 16 worldwide centers. Overall survival and progression-free survival were analyzed using Kaplan–Meier curves. Cox proportional models were used for univariate and multivariate analyses. Results: We collected data from 66 patients with metastatic sarcomatoid renal cell carcinoma receiving cabozantinib as second-line (51%) or third-line (49%) therapy. The median progression-free survival from …

MaleOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisCabozantinibPyridineschemistry.chemical_compoundRenal cell carcinomaInternal medicinemedicineHumansAnilidesPharmacology (medical)Carcinoma Renal CellSarcomatoid DifferentiationRetrospective Studiesbusiness.industryHazard ratioCell Differentiationmedicine.diseaseKidney NeoplasmsConfidence intervalOncologychemistryMale patientFemalebusinessKidney cancerTargeted Oncology
researchProduct

Sarcomatoid carcinoma of urinary bladder: Immunohistochemical study of an uncommon case

2002

A case of sarcomatoid carcinoma of the bladder is reported herein. Immunohistochemical staining with human pancytokeratin antibody was negative, while vimentin staining was strongly positive, suggesting a diagnosis of sarcoma of the bladder. Further immunohistochemical analysis revealed positivity for AE1/AE3 cytokeratins, permitting a correct diagnosis of sarcomatoid carcinoma of the bladder. It can be difficult to distinguish between sarcomatoid carcinoma, undifferentiated carcinoma and sarcoma, particularly if the biopsy specimens are of small size. In rare cases, sarcomatoid tumors may express epithelial markers different from those revealed by human pancytokeratin staining. Copyright ©…

Pathologymedicine.medical_specialtyUrinary bladder tumorAE1/AE3 cytokeratinmedicine.medical_treatmentUrologyVimentinSarcomatoid carcinomaCystectomyCytokeratinBiopsyHumansMedicineSarcomatoid carcinomaAgedUrinary bladderbiologymedicine.diagnostic_testAE1/AE3 cytokeratins; Human pancytokeratin; Sarcomatoid carcinoma; Urinary bladder tumors; Urologybusiness.industryCarcinomaSarcomamedicine.diseaseImmunohistochemistrymedicine.anatomical_structureUrinary Bladder NeoplasmsHuman pancytokeratinbiology.proteinKeratinsFemaleSarcomabusinessSpindle cell carcinoma
researchProduct